altimmune glp 1 stock sinks on mixed phase 2 MASH results for GLP-1 drug Altimmune Stock: is Its GLP-1

Roche reported positive Phase II topline data showing that its once-weekly dual glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptor agonist CT-388 achieved substantial, sustained, and dose-dependent weight loss through 48 weeks

This cohort study aims to determine whether use of glucagon-like peptide 1 receptor agonists are associated with lower risk of developing cirrhosis and its complications, including decompensation and hepatocellular cancer, among patients with ...

#GLP1 #HealthyLiving

These actions improve glycemic control and support weight loss

Weight support*

Conclusions/interpretation Our findings do not support an increased risk of SIS when taking GLP-1RA in individuals with type 2 diabetes and obesity